Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Senseonics’ Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 ...
Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...
Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients ...
Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...
Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...